Abstract
We herein report our experience of successfully managing the hemostatic system by controlling serum factor IX levels throughout the perioperative period in a patient with hemophilia B. Coronary artery bypass grafting with cardiopulmonary bypass was planned for a 52-year-old man with moderate severity of hemophilia B. During surgery, recombinant factor IX (rFIX; BeneFIX® Pfizer Japan inc., Tokyo, Japan) was administered by bolus infusion followed by continuous infusion as per the guidelines of the Japanese Society on Thrombosis and Hemostasis. The operative course was uneventful without any considerable bleeding or complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Krakow EF, Walker I, Lamy A, Anderson JAM. Cardiac surgery in patients with haemophilia B: a case report and review of the literature. Haemophilia. 2009;15:108–13.
Tourbaf KD, Bettigole RE, Zizzi JA, Subramanian S, Anderson MN. Coronary bypass in a patient with hemophilia B, or Christmas disease. J Thorac Cardiovasc Surg. 1979;77:562–9.
Mazzucco A, Stellin G, Cantele P, Boschello M, Traldi A, Gallucci V. Repair of ventricular septal defect and aortic regurgitation associated with severe hemophilia B. Ann Thorac Surg. 1986;42:97–9.
Donahue BS, Emerson CW, Slaughter TF. Elective and emergency cardiac surgery on a patient with hemophilia B. J Cardiothorac Vasc Anesth. 1999;13:92–7.
Hathaway WE, Christian MJ, Clarke SL, Hasiba U. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol. 1984;17:85–8.
Tagariello G, Davoli PG, Gajo GB, De Biasi E, Risato R, Baggio R, et al. Safety and efficacy of high-purity concentrates in hemophiliac patients undergoing surgery by continuous infusion. Haemophilia. 1999;5:426–30.
Matsusita T, Amano K, Taki M, Oka T, Sakai M, Shitahara A, et al. A guideline for the replacement therapy for acute bleeding and surgical prophylaxis of hemophilia patients without inhibitors. Nihon Kessen Shiketsu Gakkai shi. 2008;19:510–9.
Fujii T, Amano K, Atsumi T, Ishiguro A, Oohira K, Okamoto K, et al. A guideline for management of hemophilia patients without inhibitor in Japan: revised edition 2013. Nihon Kessen Shiketsu Gakkai shi. 2013;24:619–39.
Srivastava A, Brewer AK, Mauser-Bunshoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–47.
Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011;17:179–84.
Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000–2010. Haemophilia. 2012;18:46–9.
Conflict of interest
The authors have declared that no conflict of interest exists.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suzuki, T., Kawamoto, S., Kumagai, K. et al. Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy. Gen Thorac Cardiovasc Surg 64, 481–483 (2016). https://doi.org/10.1007/s11748-014-0509-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11748-014-0509-4